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Background. Under physiological conditions, the effects of
kinins in the kidney are mainly mediated by the bradykinin
B2-receptor, whereas the kinin B1-receptor is strongly induced
under inflammatory conditions in a variety of tissues. Knowledge
of the distribution of the B1-receptor along the nephron is of
importance since the B1-receptor might replace B2-receptors
under these conditions.
Methods. Using a RT-PCR/Southern blot approach allowing
relative quantification of mRNA levels, ten different microdis-
sected rat nephron segments were analyzed for the presence of
the B1- and B2-receptor before and after endotoxin treatment to
induce experimental inflammation. The functionality of the ex-
pressed receptors was assessed by kinin-induced intracellular
calcium ([Ca21]i) mobilization in microdissected nephron seg-
ments.
Results. While under physiological conditions no B1-receptor
mRNA could be detected, after 18 hours of treatment with
bacterial lipopolysaccharide (LPS) the expression of B1-receptor
mRNA was strongly induced in the efferent arteriole, the medul-
lary and inner medullary thin limb, and in the distal tubule.
Moderate expression was found in the glomerulus, proximal
convoluted and straight tubules, and in the medullary thick
ascending limb. Small but detectable expression was observed in
the cortical collecting duct. The induction of B1-receptor mRNA
expression resulted in functional receptor expression, since in-
creases in [Ca21]i were observed upon B1-agonist stimulation.
LPS treatment also increased the expression of B2-receptor
mRNA in all nephron segments except in the glomerulus, the
inner medullary thin limb and the outer medullary collecting duct.
However, no related changes in B2-agonist induced rises in
[Ca21]i were found.
Conclusions. These studies show a functional induction of the
B1-kinin receptor along the rat nephron, which should be taken in
account to address the effects of kinins under inflammatory
conditions in the kidney.
The nonapeptide bradykinin (BK1) is generated by the
proteolytic action of the serine protease kallikrein from the
protein precursor kininogen [1]. Pharmacological studies
have shown that kinins exert their biological effects through
the activation of two seven-transmembrane domain G-
protein coupled receptors, named the B1-receptor and
B2-receptor [2]. The natural agonist of the B2-receptor is
BK and its degradation by a carboxypeptidase produces the
B1-receptor agonist, [des-Arg9]-BK (DBK) [2]. The cDNA
for the B1-receptor has been recently cloned and charac-
terized in human, rabbit and mouse [3–5]. The B2-receptor
cDNA has been cloned from rat [6], mouse [7] and human
[8]. Kinins are involved in the control of a wide range of
physiological functions, including cardiovascular homeosta-
sis (regulation of systemic blood pressure and organ blood
flow), inflammatory responses, water and electrolyte trans-
port, and pain-transmitting mechanisms [9].
Most known physiological effects of kinins are mediated
through the B2-receptor, which is constitutively expressed
in many cell types [9]. In contrast, the B1-receptor, which is
not expressed at significant levels under physiological con-
ditions in most tissues, is strongly induced under patholog-
ical conditions like inflammation [10]. Tissue isolation and
exposure in vitro to pro-inflammatory cytokines induces
B1-receptor expression via a mechanism that requires
protein synthesis [11, 12]. Similarly, de novo expression of
B1-receptors occurs upon exposure to noxious stimuli such
as bacterial lipopolysaccharide (LPS), ultraviolet light, pro-
inflammatory cytokines [10], and heat stress [13]. The
observation that these stimuli induce B1-receptor expres-
sion suggests that this receptor can play a role in inflam-
matory processes, and this is supported by studies showing
that B1-receptor antagonists have antinociceptive effects in
rodent models of persistent hyperalgesia [10, 14–16]. Fur-
thermore, DBK induces polymorphonuclear leukocyte, and
to a lesser extent, mononuclear cell accumulation in inflam-
matory mouse models [17, 18].
In the kidney, the most pronounced effects of BK are the
reduction of vascular resistance, the increase in the renal
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blood flow with no change in the glomerular filtration rate,
and augmentation of natriuresis and diuresis [19–21]. A
more recent study has reported that the natriuretic and
diuretic effects of BK are due, at least in part, to the
activation of B2-receptors in the medullary thick ascending
limb of the loop of Henle [22]. In the cortical collecting
duct, BK is able to reduce the action of arginine vasopressin
(AVP) on water reabsorption by inhibiting the AVP-
induced increase in cAMP production [23].
The distribution of the B2-receptors in the kidney has
been widely studied in several species using different
techniques such as binding experiments [24, 25], autora-
diography [26], immunocytochemical studies [27] and RT-
PCR analysis [28]. More recently, the cellular localization
of B2-receptor mRNA in the human kidney by in situ
hybridization histochemistry was reported [29]. Taken to-
gether, these studies have allowed a precise localization of
the B2-receptor along the nephron, thus giving a molecular
basis for the hypothesized physiological functions of BK in
the kidney.
In contrast to the B2-receptor and despite its potential
importance in inflammation, only one study using in situ
hybridization histochemistry on human kidney describes
B1-receptor expression in the epithelial cells of the parietal
layer of Bowman’s capsule and in the thin segment of
Henle’s loop [30]. Furthermore, in cultured cells, the
B1-receptor, unlike the B2-receptor, does not desensitize
enhancing the potential role of this receptor during inflam-
matory events [31, 32]. Therefore, in a first attempt to
determine the contribution of B1-receptors to kinin-action
in the kidney, we investigated its distribution under physi-
ological and pathological conditions. No B1-receptor
mRNA expression could be detected under physiological
conditions. However, functional induction of the B1-recep-
tor in a large part of the nephron was found after endotoxin
induced inflammation. Surprisingly, this treatment also
increased the expression of B2-receptor mRNA in some
parts of the nephron, but was not associated with an
increase in BK-induced [Ca21]i mobilization. These studies
show that under inflammatory conditions in the kidney, the
effect of kinins can pass through the activation of the
B1-receptor.
METHODS
Materials
Bradykinin (BK), DBK and angiotensin II (Ang II) were
from Sigma and used at a concentration of 0.1 mM. B1-
receptor antagonist des-Arg9-Leu8BK was from Sigma and
used at a concentration of 1 mM and HOE-140 (B2-
antagonist) was a generous gift from Prof. B. Scho¨lkens
(Hoechtst, Frankfurt, Germany) and was used at concen-
tration of 1 mM.
Animals and lipopolysaccharide treatment
Experiments were performed on male Sprague-Dawley
rats (Iffa Credo, France), five weeks old and weighing 120
to 140 g. LPS-treatment was performed by one intraperi-
tonal injection of LPS (2 mg/kg; Sigma) 18 hours before
sacrifice. LPS was used at a concentration of 10 mg/ml in a
0.9% saline solution. Control animals were injected with
0.9% saline solution only. Fourteen rats were randomly
divided into two groups of which 7 were treated with LPS
and 7 served as the controls.
Microdissection of nephron segments
Animals were anesthetized with an intraperitonal injec-
tion of pentobarbital (60 mg/kg; Sanofi, France). Kidneys
were microdissected as previously described [33]. The
abdominal aorta was cannulated with polyethylene tubing
just below the left kidney. The left kidney was perfused with
10 ml of ice-cold solution-1 (135 mM NaCl, 1 mM Na2SO4,
1.2 mM Mg SO4, 5 mM KCl, 2 mM CaCl2, 5.5 mM glucose,
and 5 mM Hepes pH 7.4) followed by perfusion with 10 ml
of solution-1 containing 1 mg/ml collagenase (0.38 U/mg
collagenase A; Boehringer Mannheim) and 1 mg/ml bovine
serum albumin (BSA; Sigma). The left kidney was removed
and several coronal sections over the entire cortico-papil-
lary axis were made. These sections were cut into three
pieces: cortex, outer medulla, and inner medulla. The
different pieces were transferred into individual tubes
containing solution-1 with 0.5 mg/ml collagenase and 1
mg/ml BSA. The tubes were incubated for 8 to 15 minutes
at 37°C in a shaking water bath and their contents were
continuously bubbled with 95% O2/5% CO2. These differ-
ent kidney tissue pieces were dissected on ice under a
microscope and transferred to solution-1 containing 10 mM
of vanadyl ribonucleotide complex (Sigma), a potent
RNase inhibitor, and were placed on ice until further use.
Parts of the following segments were isolated: efferent
arteriole (EA), glomerulus (Glom), proximal convoluted
tubule (PCT), proximal straight tubule (PST), medullary
thin descending limb (MTL), inner medullary thin limb
(IMTL), medullary thick ascending limb (MTAL), distal
tubule (DT), and cortical and outer medullary collecting
ducts (CCD and OMCD, respectively).
Morphometry of nephron segments
The surface of the microdissected nephron segments was
determined using photographs of freshly isolated nephron
segments at 363 magnification, using an image-morphom-
etry system (BIOSTATy, Toulouse, France). The determi-
nation of the surface of each segment was repeated five to
seven times.
Reverse transcription
For reverse transcription (RT), one glomerulus (surface
480 6 80 mm2) or a total surface of 480 6 89 mm2 of each
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renal tubule segment was transferred to a reaction tube
with 10 ml of an ice-cold solution containing 1 U/ml of
human placental RNase inhibitor (Pharmacia) and 5 mM
dithiothreitol (DTT; Gibco-BRL). Genomic DNA was
degraded in the following way. Reaction tubes containing
the different nephron segments were centrifuged for one
minute (10,000 rpm). The RNase-inhibitor solution was
replaced by 9 ml of a solution containing 2% Triton X-100,
1 U RNase inhibitor, 5 mM DTT and 3 U RNase-free
DNase (Promega) was added and incubated at 37°C for 30
minutes to permeabilize the cells and to digest the genomic
DNA. For first-strand cDNA synthesis the following com-
ponents were added (final reaction volume 100 ml): 0.5 mg
pd(T)15, 32 U RNase inhibitor, 25 mM DTT, 5 mM dNTPs,
RT buffer and 200 U reverse transcriptase (M-MLV; Gibco
BRL). After RNA denaturation (7 min, 70°C), the reaction
was carried out at 42°C for 50 minutes in a Perkin Elmer
Thermo Cycler 480, heated to 95°C for five minutes and
chilled on ice.
Polymerase chain reaction
For the polymerase chain reaction (PCR), 10 ml of each
cDNA preparation was amplified. PCR amplification was
performed in Taq-buffer (Appligene) in a final volume of
100 ml by adding 140 pM of each oligonucleotide, and 2 U
Taq polymerase (Appligene) and 0.5 mM dNTPs.
For B1-receptor cDNA amplification, samples were de-
natured for two minutes and 30 seconds at 93°C. Then the
PCR was performed for 35 cycles (1 min at 95°C, 1 min and
30 seconds at 62°C, 1 min at 72°C) followed by incubation
for 10 minutes at 72°C. The sequences of the oligonucleo-
tides used for B1-receptor cDNA amplification were de-
signed to be located in the coding region of the rat
B1-receptor (Genbank, accession number U66107). The
sequence of the sense oligonucleotide was 59-CTACAG-
GCTCCTGGTATACC-39 (bases 435 to 454, relative to B1
start codon) and of the antisense oligonucleotide 59-CT-
CAGGGAGGCCAGGATGTG-39 (bases 700 to 719).
As described previously [34], the B2-receptor cDNA
samples were denatured for two minutes and 30 seconds at
95°C, then the PCR was performed for 35 cycles (1 min at
95°C, 1 min and 30 seconds at 59°C, 1 min at 72°C) followed
by 10 minutes at 72°C. The B2-receptor oligonucleotides
were designed based on the 39 untranslated region of the
cDNA from the sequence of the rat gene [6]. The sense
oligonucleotide was defined by bases 2955-2975 (relative to
B2 start codon, 59-ACCAGAGATAGGATAGCCTTC-39)
and the antisense oligonucleotide was defined by bases
3451-3473 (59-ACAGTGTGTTAGCCTCAGAAGC-39).
For glyceraldehyde-3-phosphate-dehydrogenase (GAPDH)
amplification, samples were denatured for three minutes at
94°C, then PCR was performed for 27 cycles (1 min at 95°C,
1 min and 30 seconds at 57°C, 1 min at 72°C) followed by
10 minutes at 72°C. The GAPDH oligonucleotides were
designed from the rat gene. The sequences of the GAPDH
oligonucleotides were defined by bases 439 to 458 (relative
to GAPDH start codon, 59-AATGCATCCTGCACCAC-
CAA-39, sense) and by bases 889 to 909 (59-GTCATT-
GAGAGCAATGCCAGC-39, antisense).
The predominant cDNA amplification products were
predicted to be 285 bp and 518 bp in length for the
B1-receptor and B2-receptor, respectively. The expected
size of the product for GAPDH is 470 bp. The PCRs for the
B1- and B2-receptors and GAPDH were performed on the
same cDNA. The PCR was carried out using a Perkin
Elmer Thermal Cycler (model 480).
Southern blot analysis
Thirty microliters of each PCR reaction were electropho-
rized through a 1.8 to 2% agarose gel. The gel was
denatured, neutralized and blotted overnight onto a nylon
membrane (HybondTM-N; Amersham) with 20 3 SSC
(sodium chloride/sodium citrate) as the transfer buffer. The
DNA was fixed to the membrane under UV radiation (254
nm) in an UV-crosslinker (Stratagene). The membranes
were hybridized with nested B1- and B2-receptor probes.
The sequences of these B1- and B2-receptor probes were:
59-CCTTGCAAAGTGCCAAGC-39 and 59-CGTTAAGT-
TTATCACAGG-39, respectively. The probes were end-
labeled with [g32P]-ATP (4500 Ci/ml) by the use of T4
polynucleotide-kinase (Promega). Membranes were prehy-
bridized overnight at 42°C in 50 mM phosphate buffer pH
6.5 containing 50% deionized formamide, 5 3 SSC, 5 3
Denhardt’s reagent (Sigma), and 50 mg/ml of denaturated
salmon sperm DNA (Sigma). Hybridization was performed
overnight at 42°C in 20 mM phosphate buffer pH 6.5
containing 50% deionized formamide, 5 3 SSC, 1 3
Denhardt’s reagent, and 50 mg/ml of denatured salmon
sperm. After hybridization, the membrane was washed with
2 3 SSC/0.1% SDS once at room temperature and twice at
65°C for 30 minutes. Autoradiography was performed for
five hours at 280°C using Kodak XAR-5 films and inten-
sifying screens.
Relative quantification
The densitometric values of each band were calculated
using the Personal Densitometer SI of Molecular Dynam-
ics. B1- and B2-receptor signals were corrected for differ-
ences in loading by normalization with GAPDH. Prelimi-
nary experiments have shown a linear non-saturating
increase in amplification products between cycles 25 and 40
for the B1-receptor and between cycles 20 and 35 for
GAPDH (not shown). These relationships were deter-
mined as described previously for the relationship between
the quantity of B2-receptor mRNA and that of its amplifi-
cation product [34]. Thus, performing RT-PCR/Southern
blot experiments within these amplification boundaries
with GADPH as the loading control allows a relative
quantitative evaluation of the expression of B1- and B2-
receptor mRNA.
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Measurement of the intracellular Ca21 mobilization
The intracellular calcium ([Ca21]i) mobilization mea-
surements were performed as described previously [33]. In
brief, the microdissected renal tubule segments were indi-
vidually transferred onto a thin glass microscope coverslip
in 1 ml of solution-1 containing 1% agarose (Sigma; type
IX) at 37°C. Then the agarose was jellied by cooling the
coverslip for one minute on ice. The samples embedded in
agarose were loaded with 5 mM fura-2 acetylmethoxy ester
(fura-2/AM) at room temperature for one hour. For fluo-
rescence measurements, each sample was placed on the
stage of an inverted microscope and was continuously
perfused at a rate of 0.6 ml/min at 37°C with solution-1,
which could be replaced at any time by the solutions to be
tested. Fura-2 was alternatively excited at 340 and 380 nm
using a 75W xenon light source, filters, and a chopper (PTI
Photoscan II System, Kontron). The illumination path
included a 403 objective (Nikon) and an ultraviolet di-
chroic mirror. Emitted signals passed through a 480 6 20
nm bandpass filter before detection by a photomultiplier
and were recorded every 2 seconds. The fluorescence
intensities (S at 340 nm and L at 380 nm) were recorded
from about 15% of the total glomerulus or tubule segment
area and controlled by an adjustable window diaphragm.
Correction for autofluorescence was performed as de-
scribed [35]. [Ca21]i was calculated from the equation of
Grynkiewicz et al [36]. [Ca21]i 5 Kd [(R 2 Rmin)/(Rmax 2
R)] (Lmax/Lmin) where Kd (5 224 nM) is the dissociation
constant of fura-2 for calcium, r 5 S/L, Rmin and Rmax are
values of R at 0 and saturating calcium concentrations,
respectively, and Lmax/Lmin is the ratio of L at 0 and
saturating calcium concentrations. Rmin, Rmax, Lmax and
Lmin are constant parameters that depend on the optical
system used. Under our conditions these values were: Rmin
5 0.96, Rmax 5 9.21, Lmax/Lmin 5 6.38.
Statistical analysis
Results are given as mean 6 SEM. The differences were
tested using the non-parametric Mann-Whitney U-test
which was used for comparison between two unpaired
variables. P , 0.05 was considered significant.
RESULTS
Distribution of B1-receptor mRNA along the nephron
from rats treated with LPS
While in microdissected nephron segments of nontreated
control rats no B1-receptor mRNA could be detected (data
not shown), 18 hours of LPS (2 mg/kg) treatment induced
in all but one segment B1-receptor mRNA expression (Fig.
1A). B1-receptor mRNA expression was studied by RT-
PCR followed by Southern blot analysis using a nested
B1-receptor probe. Moreover, to verify that the samples
were not contaminated by genomic DNA, RNA samples
were submitted to the RT-PCR amplification without the
reverse transcriptase enzyme. In those samples no bands
were observed except those of the primers at the bottom of
the gel (not shown). Except in the OMCD, a single band of
predicted size (285 bp) was found in all microdissected
nephron segments. In order to perform a relative quantifi-
cation of the expression of B1-receptor PCR products and
to analyze the integrity of the mRNA, we amplified in
parallel a housekeeping gene, that of GAPDH, and ana-
lyzed its expression in ethidium bromide stained gels (Fig.
1B). The amplification product of GAPDH was found in all
renal structures at the predicted size of 470 bp. After
densitometric analysis, B1-receptor mRNA expression was
corrected using GAPDH and expressed as the percentage
of the B1-receptor mRNA expression in the efferent arte-
riole in which the largest B1-receptor mRNA signal was
observed (Fig. 2). As evaluated by our relative quantitative
method, large signals for B1-receptor mRNA were de-
tected in the EA, MTL, IMTL and DT. Moderate signals
were found in the Glom, PCT, PST, and MTAL. A small,
but detectable signal was found in the CCD.
Fig. 1. B1-receptor and GAPDH mRNA
expression in nephron segments of
lipopolysaccharide (LPS)-treated rats. Rats
were treated for 18 hours with 2 mg/kg LPS
followed by nephron segment isolation using
microdissection. Chromosomal DNA was
degraded and samples were in parallel
subjected to RT-PCR analysis for GAPDH
mRNA expression and RT-PCR/Southern blot
analysis for B1-receptor mRNA expression. (A)
B1-receptor mRNA expression (revealed by
means of a nested B1-receptor probe). (B)
GAPDH mRNA expression (revealed by
ethidium bromide staining). One representative
experiment is shown.
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B1-agonist-induced intracellular calcium mobilization
[Ca 21]i
To verify whether induction of B1-receptor mRNA is
translated into functional B1-receptors, the ability of B1-
agonist DBK to mobilize intracellular calcium in the mi-
crodissected nephron segments was examined. Although
with our method we were unable to detect B1-receptor
mRNA in nephron segments of control rats, DBK-induced
calcium mobilization was observed in the MTAL and the
CCD (Fig. 3, insets; Table 1), which was prevented by the
B1-antagonist des-Arg9-Leu8BK (not shown). The other
nephron segments of control rats did not respond to DBK
(Table 1).
Except for PCT and PST, all LPS-treated segments in
which an increase of B1-receptor mRNA was detected,
responded to an addition of DBK (0.1 mM) by mobilization
of intracellular calcium (Fig. 3, traces marked a; Table 1).
However, the amplitudes of the calcium responses after
DBK-addition in the MTAL and the CCD were not
significantly different between control and LPS-treated rats
(Table 1). The shapes and amplitudes of the calcium
responses obtained in the nephron segments were differ-
ent. The [Ca21]i increase was large in the glomerulus,
MTL, IMTL and DT, and smaller in the EA, MTAL and
CCD. The EA, glomerulus, IMTL and DT showed a
biphasic response composed of a sharp peak followed by a
sustained phase. In the MTL and CCD, the sustained phase
was less pronounced. In the MTAL the biphasic response
was characterized by a small initial peak followed by a
pronounced sustained phase. In LPS-treated rats, basal
[Ca21]i levels were around 90 nM with the lowest value in
the EA (40 6 5 nM) and highest in the MTL (125 6 25 nM).
Peak values were between 133 6 11 nM in the EA and
536 6 34 nM in IMTL (Table 1). The B1-agonist induced
intracellular calcium mobilization was specific for the B1-
receptor, since it could be abolished by B1-antagonist
des-Arg9-Leu8BK (1 mM) pretreatment (added 5 min be-
fore and during B1-agonist (0.1 mM) stimulation; Figure 3,
traces marked b). The absence of DBK-induced calcium
responses in the PCT and PST is not specific for the
B1-receptor and might be related to the experimental
conditions used. Angiotensin II (Ang II), which is known to
induce a calcium response along the rat nephron [37], was
used as a control and was effective in all the microdissected
nephron segments except in the PCT and PST (not shown).
Effect of LPS on the expression of B2-receptor mRNA
along the nephron
Figure 4 shows a typical pattern of the distribution of the
B2-receptor mRNA along the nephron of control rats (Fig.
4A) and LPS-treated (18 hr) rats (Fig. 4C). A single band
of 518 bp was found in the EA, Glom, PCT, PST, MTL,
IMTL, MTAL, DT, CCD and OMCD. Interestingly, using
our RT-PCR/Southern blot approach, we have localized
B2-receptor mRNA expression in the EA, MTL and
OMCD, three nephron structures where to our knowledge
the presence of B2-receptor mRNA has never been de-
scribed. As described above for the B1-receptor, samples
were analyzed for contaminating genomic DNA by per-
forming the RT-PCR amplification without the reverse
transcriptase enzyme. In those samples no bands were
observed except those of the primers at the bottom of the
gel (not shown). As described for B1-receptor mRNA,
GAPDH mRNA expression amplified in parallel was de-
tected in all renal structures (Fig. 4B and 4D). The
evaluation of the relative variation between B2-receptor
mRNA expression of control and LPS treated animals is
shown in Figure 5. The densitometric values are presented
as the percentage of EA value obtained in LPS treated rats.
Whereas no significant variation in B2-mRNA expression
was observed between control and LPS treated rats in the
Glom and OMCD, surprisingly, we found a significant
increase in B2-receptor mRNA expression in the EA, PCT,
PST, MTL, MTAL, DT and CCD. On the contrary, a net
decrease in B2-receptor mRNA expression was observed in
the IMTL segment.
Intracellular calcium mobilization induced by B2-
receptor agonist
Bradykinin induced an increase in [Ca21]i in all segments
except in the PCT and PST (Table 2). As described
previously [38], BK induced a biphasic calcium response
consisting of a transient phase followed by a sustained
phase. A typical profile obtained from an IMTL segment of
Fig. 2. Relative quantification of B1-receptor mRNA expression. One
glomerulus (surface 480 6 80 mm2) or a total surface of 480 6 89 mm2 of
each renal tubule segment was used. Band intensities were scanned (4
times) using a densitometer. B1-receptor mRNA expression was corrected
using GAPDH, amplified in parallel, and expressed as the percentage of
B1-receptor mRNA expression in the efferent arteriole (EA). Values are
means 6 SEM of seven experiments.
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Fig. 3. Representative recordings of intracellular calcium mobilization in response to DBK along the nephron of LPS-treated rats (18 hr, 2 mg/kg).
Shown are traces stimulated with DBK (0.1 mM) without (a) and with (b) B1-antagonist des-Arg9-Leu8BK (1 mM, added 5 min before and during DBK
stimulation). Insets in the MTAL and CCD show the responses to 0.1 mM DBK in segments of control rats (treated with vehicle only). In the other parts
of the nephron no responses to DBK were obtained in control rats. Mean peak values are shown in Table 1.
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control rats is shown in Figure 6 (control, trace a). The
observed calcium mobilization induced by BK-stimulation
is due to the activation of B2-receptors since the calcium
response was abolished with HOE-140 a specific B2-recep-
tor antagonist (Fig. 6, control, trace b) and not by the
specific B1-antagonist des-Arg9-Leu8BK (not shown). The
basal calcium level in individual segments was between
39 6 12 nM in the EA and 135 6 11 nM in the MTAL and
the peak values were between 62 6 15 nM in the EA and
443 6 28 nM in the IMTL (Table 2). Since LPS treatment
led to B2-receptor mRNA variations in some nephron
segments, we have examined if those variations were asso-
ciated with any modification in the [Ca21]i response in-
duced by BK-stimulation. As shown in Table 2, no varia-
tions in the calcium response were observed after LPS
treatment. Moreover, the decrease in B2-mRNA expres-
sion observed in the IMTL segments is not associated to a
significant decrease in the calcium response (Fig. 6; LPS,
trace a).
DISCUSSION
All components of the kallikrein-kinin system are
present in the kidney [1] and it is well established that
kinins contribute to renal hemodynamics and excretory
function [39]. Since all kinin-effects are mediated by spe-
cific receptors, the precise localization of kinin-receptors
along the nephron allows a better understanding of the
actions of BK in the kidney. B2-receptor distribution along
the nephron has been extensively studied since this recep-
tor mediates the larger part of the kinin-responses under
Fig. 4. B2-receptor and GAPDH mRNA
expression in nephron segments of control and
LPS-treated rats. Rats were treated for 18
hours with 2 mg/kg LPS or with vehicle only
followed by nephron segment isolation using
microdissection. Chromosomal DNA was
degraded and samples were in parallel
subjected to RT-PCR analysis for GAPDH
mRNA expression and RT-PCR/Southern blot
analysis for B2-receptor mRNA expression. B2-
receptor mRNA expression (revealed by means
of a nested B2-receptor probe) in control (A)
and LPS-treated rats (C). GAPDH mRNA
expression (revealed by ethidium bromide
staining) in control (C) and LPS-treated rats
(D). One representative experiment is shown.
Table 1. Effect of DBK (0.1 mM) on intracellular Ca21 concentration ([Ca21]i) in the different microdissected nephron segments obtained from
untreated (control) and treated rats (LPS) 18 hours with LPS 2 mg/kg
Nephron
segment EA Glom PCT PST MTL IMTL MTAL DT CCD
Control
Basal 38 6 7 82 6 12 104 6 11 96 6 9 119 6 9 113 6 13 69 6 8 116 6 12 78 6 7
Peak 41 6 9 79 6 11 100 6 7 102 6 13 121 6 10 108 6 8 133 6 12 112 6 9 154 6 15
LPS
Basal 40 6 5 85 6 16 102 6 14 107 6 17 125 6 25 115 6 12 73 6 11 115 6 15 83 6 9
Peak 133 6 11a 241 6 25a 112 6 19a 116 6 22 437 6 18a 536 6 34a 140 6 15 272 6 17a 161 6 8
Abbreviations are in the Appendix. [Ca21]i values are expressed in nM. Data are mean 6 SEM of 4 independent experiments.
a P , 0.05 when compared to the respective peak control value
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physiological conditions [24, 25, 27–29]. Under physiologi-
cal conditions the B1-receptor is not expressed at signifi-
cant levels, but its expression is often induced during
inflammation. For example, studies on B1-receptor func-
tion in the cardiovascular and pulmonary systems have
revealed a clear link between B1-receptor induction and
the cytokine network [10]. In this respect an increase in
inflammatory factors (chemokines, cytokines) released
from resident or infiltrating cells such as monocyte/macro-
phages, neutrophils and T cells [40, 41] is observed in a
number of renal diseases (glomerulonephritis, lupus ne-
phritis, renal transplant rejection, ischemia, HIV nephrop-
athy and acute hypertensive nephritis). Although it remains
to be demonstrated, the B1-receptor might be induced in
these renal diseases. Despite this potential importance of
the B1-receptor under inflammatory conditions in the
kidney, nothing is known about the renal localization of the
B1-receptor. Therefore, in an attempt to better understand
the role of the renal B1-receptor we studied the precise
localization of the B1-receptor along the rat nephron under
physiological and inflammatory conditions using microdis-
sected nephron segments. Experimental inflammation was
induced by 18 hours of LPS treatment, which is usually
sufficiently long to induce B1-receptor induction in differ-
ent tissues [10].
Our data suggest differences in B1-receptor coupling and
translational control along the different parts of the
nephron. In the MTAL and the CCD of control rats a
calcium response to DBK was observed, although no
corresponding B1-receptor mRNA was detected under our
experimental conditions. This indicates that under normal
conditions in these segments, the small basal number of
B1-receptors are efficiently coupled to the PLC-transduc-
tion pathway that was not changed by the induction of new
B1-receptor mRNA after LPS treatment. In the other
segments, de novo B1-receptor mRNA induction is directly
coupled to a de novo functional B1-receptor response
(calcium mobilization). However, there is no direct rela-
tionship between B1-receptor mRNA levels and the ampli-
tude of the calcium response, again indicating this segmen-
tal regulation. Detailed studies are necessary to decorticate
these segmental control mechanisms, but are out of the
scope of this study. The absence of both DBK and Ang
II-induced calcium responses in the proximal tubules might
be due to the microdissection conditions used. Microdis-
section in the presence of collagenase, indispensable for
nephron segment preparation, can result in irreproducible
calcium responses in the proximal tubules [37]. Omitting
collagenase during microdissection restores this response
for Ang II [37], but interferes in the comparison between
different segments.
Whereas this study was not designed to determine the
pathophysiological significance of the presence of the B1-
receptor in the different parts of the nephron, it shows that
the effects of kinins may pass through this receptor-subtype
under inflammatory conditions. In this respect, using iso-
lated perfused rat kidneys, conditions (that is, ischemia and
surgery) known to favor B1-receptor induction in other
tissues [10], Guimares et al have reported that the B1-
agonist DBK increased renal vascular resistance [42]. The
authors have postulated that B1-kinin receptor responses
may be of importance in the generation and/or the main-
tenance of renal vasoconstriction in disease states that lead
to renal failure. In this context, the increased vascular
resistance might originate from the vasoconstriction of the
EA induced by the presence of B1-receptors under these
conditions. This is consistent with our observation that
experimental inflammation induces a high-level B1-recep-
tor mRNA expression in the EA. Furthermore, it has been
hypothesized that under pathological conditions, the B1-
receptor could amplify or replace the function of the
B2-receptor [10], which, unlike the B1 [31, 32], desensitizes
upon prolonged B2-agonist stimulation [43]. The induction
of B1-receptor mRNA at the glomerular level is of partic-
ular interest since it has been reported that in primary
culture of mesangial cells the B1-agonist stimulates cell
proliferation [38]. The presence of B1-receptors on these
cultivated cells without LPS treatment can be explained by
the fact that the mesangial cell has an inflammatory
character in culture [44], conditions that favor the induc-
tion of the B1-receptor in other tissues. Moreover, DBK is
able to stimulate the formation of collagen in cultured
human lung fibroblasts [45]. Such effects have to be related
to renal pathologies where fibrotic processes are observed.
Fig. 5. Relative quantification of B2-receptor mRNA expression. B2-
receptor mRNA expression was corrected using GADPH, amplified in
parallel, and expressed as the percentage of B2-receptor mRNA expres-
sion in the efferent arteriole (EA) of LPS-treated rats. Abbreviations are
in the Appendix. Symbols are: (f) B2, control nephron segments; (M)
LPS-treated nephron segments. Values are means 6 SEM of seven
experiments.
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Compared to other work on the B2-receptor, based
either on binding or immunohistological studies [25, 27,
29], our approach, RT-PCR/Southern blot analysis allowing
relative quantification of B2-receptor expression in micro-
dissected nephron segments, appears to be more sensitive
and permits complementary information, since we have
been able to detect B2-receptor mRNA expression in three
new nephron segments: the EA, the MTL and the OMCD.
BK is known to reduce both afferent and efferent glomer-
ular arteriolar tone, with the most pronounced decreases in
the afferent arteriole [46], thus suggesting the presence of
B2-receptors in these structures. The presence of B2-
receptors in the afferent arteriole was recently confirmed
[27], and here we provide a molecular basis for the ob-
served actions of BK in the efferent arteriole: the presence
of functional B2-receptors. The functions of BK in the
medullary thin limb and outer medullary collecting duct are
not yet known, but the presence of B2-receptors suggest
contribution of these segments to the natriuretic and
diuretic effects of BK. Whereas it has been reported that
BK increases [Ca21]i in cultured proximal tubular cells [47],
no BK- or Ang II-induced [Ca21]i increase in the proximal
tubule segments could be observed under our experimental
conditions. As discussed for the B1-receptor above, the
absence of any receptor specific response is most likely due
to the microdissection conditions.
Alhough based on a relatively quantitative approach, the
increased B2-receptor mRNA expression in the EA, PCT,
PST, MTL, MTAL, DT and CCD, and decreased B2-
mRNA expression in the IMTL after LPS treatment are
worth being discussed. Whereas no previously published
data were available on the effects of LPS on B2-receptor
expression in renal cells, it has been reported that synovial
cells that are insensitive to BK stimulation under basal
conditions became responsive to BK (stimulation of PGE2
release) after pretreatment with the cytokine IL-1b [48].
This effect was abrogated by cycloheximide and actinomy-
cin D, strongly suggesting a de novo B2 receptor synthesis
following cytokine treatment [48]. In our experiments, the
changes in B2-receptor mRNA expression were not accom-
panied by a changed functional response as determined by
the mobilization of intracellular calcium. As described
above for the B1-receptor, these data suggest differences in
B2-receptor translational control and receptor coupling
along the nephron segments. Furthermore, up-regulated
B2-receptors can be specifically coupled as we have shown
recently in rat mesangial cells in which cAMP induces
B2-receptor expression that is coupled to the PLA2 path-
way and not to the PLC pathway [49]. Therefore, selective
up- or down-regulation of only one B2-receptor transduc-
tion pathway remains a possibility to be investigated to
account for a segmental regulation of B2-receptors along
the nephron.
Table 2. Effect of BK (0.1 mM) on intracellular [Ca21]i concentration in the different microdissected nephron segments
Nephron
segment EA Glom PCT PST MTL IMTL MTAL DT CCD OMCD
Control
Basal 39 6 12 98 6 15 101 6 9 105 6 12 104 6 26 111 6 19 135 6 11 76 6 14 92 6 13 122 6 24
Peak 62 6 15 283 6 32 98 6 11 112 6 13 320 6 32 443 6 28 275 6 40 109 6 8 144 6 12 223 6 12
LPS
Basal 43 6 7 115 6 12 111 6 13 103 6 16 96 6 17 100 6 12 132 6 9 85 6 13 102 6 14 116 6 20
Peak 68 6 12 277 6 27 107 6 15 115 6 18 327 6 29 395 6 33 267 6 35 113 6 12 151 6 16 232 6 19
Abbreviations are in the Appendix. [Ca21]i values are expressed in nM. Data are mean 6 SEM of 4 independent experiments.
Fig. 6. Typical recordings of intracellular
calcium mobilization in response to 0.1 mM BK
in control and LPS-treated rats in the inner
medullary thin limb (IMTL). Shown are traces
stimulated with BK without (a) and with (b)
B2-antagonist HOE-140 (1 mM, added 5 min
before and during BK stimulation). Thin line is
5 minutes of BK; heavy line is ten minutes of
HOE-140. Mean peak values are shown in
Table 2.
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From a therapeutical point of view, the precise distribu-
tion of the B1- and B2-receptor along the nephron should
be of great help in extending our knowledge of the mech-
anism of the protective effect of the angiotensin converting
enzyme inhibitors (ACE-inhibitors), which not only de-
crease Ang II formation but also retard kinin catabolism.
Chronic administration of ACE-inhibitors markedly atten-
uates the development of glomerular lesions in different
models of progressive glomerular sclerosis [50]. In subtotal
nephrectomized rats that were performed to mimic a loss of
renal mass, we demonstrated that ACE-inhibitors delay
selectively the evolution of tubular hypertrophy in the
proximal tubule [51]. Whether a kinin mechanism is in-
volved in these anti-hypertrophic effects of ACE-inhibitors
cannot be demonstrated at present. In this respect, we have
recently reported that the B1-agonist induced the expres-
sion of its own receptor in human lung fibroblast cells [52].
Thus, ACE-inhibitor treatment, which increases the kinin
concentration in several tissues including kidney [53], can
lead to increased B1-receptor expression. Indeed, pretreat-
ment of rabbits with ACE-inhibitors made these animals
responsive to DBK, and it was suggested that potentiation
of endogenous kinins would ‘prime’ the expression of
B1-receptors [54].
In conclusion, our studies show, to our knowledge for the
first time, the localization of bradykinin B1-receptors along
the rat nephron. Although absent under physiological
conditions, functional B1-receptors were found along the
nephron under inflammatory conditions. This suggests that
in inflammatory renal diseases, the effects of kinins may
pass through B1-receptors.
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APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; BK,
bradykinin; [Ca21]i, intracellular calcium concentration; CCD, cortical
collecting duct; DBK, des-Arg9bradykinin; DT, distal tubule; EA, efferent
arteriole; glom, glomerulus; HOE-140 (D-Arg-(Hyp3,Thi5,D-Tic7,Oic8)-
BK); IMTL, inner medullary thin limb; LPS; lypopolysaccharide; MTAL,
medullary thick ascending limb; MTL, medullary thin descending limb;
OMCD, outer medullary collecting duct; PCT, proximal convoluted
tubule; PST, proximal straight tubule.
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